The phase 3 ADAPT study (NCT03669588) has recently demonstrated that efgartigimod, a novel FcRn inhibitor, is well tolerated in AChR-seropositive MG with significant improvements in MG-ADL and QMG scores [28]. This evidence concerns the gene FCGRT and myasthenia gravis.